Current clinical trials

Current clinical trials

A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study of Continued Enzalutamide Treatment Beyond Progression in Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.
Status: Ongoing but not recruiting
Condition: Prostate cancer
More Info: Click here
A Multinational, Phase 3, Randomized, Double Blind, Placebo Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration Resistant Prostate Cancer.
Status: Recruiting
Condition: Prostate cancer
More Info: Click here
A Multicenter, Single-Arm, Open-Label, Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects With Metastatic Castration-ResistantProstate Cancer (mCRPC) Treated With Enzalutamide Who Are at Potential Increased Risk of Seizure.
Status: Recruiting
Condition: Prostate cancer
More Info: Click here
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer(The METRIC Study).
Status: Recruiting
Condition: Breast cancer
More Info: Click here
A Randomized, Double-Blind, Phase 3 Study of the Janus Kinase (JAK) 1/2 Inhibitor, Ruxolitinib, or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 1 Study)
Status: Recruiting
Condition: Pancreas cancer
More Info: Click here 
Phase 1/2a Dose-Escalation Study of CRLX301 in Patients With Advanced Solid Tumor Malignancies..
Status: Not yet recruiting
Condition: Various cancers
More Info: Click here
A Phase 3 Randomized, Double-blind Study Of Pf 06439535 Plus Paclitaxel-carboplatin And Bevacizumab Plus Paclitaxel -Carboplatin For The First-line Treatment Of Patients With Advanced Non-squamous Non-small Cell Lung Cancer.
Status: Recruiting
Condition: Lung cancer
More Info: Click here
A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men With High-Risk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy.
Status: Recruiting
Condition: Prostate cancer
More Info: Click here
A Study of MPDL3280A (Anti-Programmed Death Ligand 1 [PD-L1] Antibody) in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma.
Status: Not yet recruiting
Condition:  Kidney cancer
More Info: Click here
Randomised Phase 3 Trial of Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer: ENZAMET.
Status: Not yet recruiting
Condition: Prostate cancer
More Info: Click here
A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours.
Status: Recruiting
Condition: Testis cancer
Randomised phase II trial of neoadjuvant chemotherapy +/- concurrent aromatase inhibitor endocrine therapy to downstage large oestrogen receptor negative breast cancer (ELIMINATE).
Status: Recruiting
Condition: Breast cancer
A Prospective Randomised, Open Label, Blinded Endpoint (PROBE) Study to Evaluate DUAL Antithrombotic Therapy With Dabigatran Etexilate (110mg and 150mg b.i.d.) Plus Clopidogrel or Ticagrelor vs. Triple Therapy Strategy With Warfarin (INR 2.0 - 3.0) Plus Clopidogrel or Ticagrelor and Aspirin in Patients With Non Valvular Atrial Fibrillation (NVAF) That Have Undergone a Percutaneous Coronary Intervention (PCI) With Stenting.
Status: Not yet recruiting
Condition: Atrial fibrillation
More Info: Click here
Effect of ivabradine versus placebo on cardiac function, exercise capacity, and neuroendocrine activation in patients with Chronic Heart Failure with Preserved left ventricular Ejection Fraction: An 8 month, randomised doubleblind placebo controlled, international, multicentre study.
Status: Recruiting
Condition: Heart failure
Role of non-coding RNA in differentiating aggressive from non-aggressive prostate cancer - Prostate cancer Bio-bank for Biomarker Discovery Program.
Status: Recruiting
Condition: Prostate cancer
Improving Sunitinib Efficacy and tolerability in patients with metastatic clear cell carcinoma of the kidney by using a 14/7 day schedule and Toxicity-Adjusted Dosing.  
Status: Not yet recruiting
Condition: Kidney cancer
Back to the top of this page